Active NF-κB signalling is a prerequisite for influenza virus infection

  • Falk Nimmerjahn
    Institut für Klinische Molekularbiologie und Tumorgenetik, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistr. 25, D-81377 München, Germany
  • Diana Dudziak
    Institut für Klinische Molekularbiologie und Tumorgenetik, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistr. 25, D-81377 München, Germany
  • Ulrike Dirmeier
    Abteilung Genvektoren, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistraße 25, D-81377 München, Germany
  • Gerd Hobom
    Methesys GmbH, Gottfried-Hagen-Straße 60, D-51105 Köln, Germany
  • Alexander Riedel
    Klinische Kooperationsgruppe, Pädiatrische Tumorimmunologie, Kinderklinik, Universitätsklinikum der Technischen Universität München, Marchioninistr. 25, D-81377 München, Germany
  • Martin Schlee
    Institut für Klinische Molekularbiologie und Tumorgenetik, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistr. 25, D-81377 München, Germany
  • Louis M. Staudt
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
  • Andreas Rosenwald
    Pathologisches Institut, Universität Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
  • Uta Behrends
    Klinische Kooperationsgruppe, Pädiatrische Tumorimmunologie, Kinderklinik, Universitätsklinikum der Technischen Universität München, Marchioninistr. 25, D-81377 München, Germany
  • Georg W. Bornkamm
    Institut für Klinische Molekularbiologie und Tumorgenetik, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistr. 25, D-81377 München, Germany
  • Josef Mautner
    Klinische Kooperationsgruppe, Pädiatrische Tumorimmunologie, Kinderklinik, Universitätsklinikum der Technischen Universität München, Marchioninistr. 25, D-81377 München, Germany

抄録

<jats:p>Influenza virus still poses a major threat to human health. Despite widespread vaccination programmes and the development of drugs targeting essential viral proteins, the extremely high mutation rate of influenza virus still leads to the emergence of new pathogenic virus strains. Therefore, it has been suggested that cellular cofactors that are essential for influenza virus infection might be better targets for antiviral therapy. It has previously been reported that influenza virus efficiently infects Epstein–Barr virus-immortalized B cells, whereas Burkitt's lymphoma cells are virtually resistant to infection. Using this cellular system, it has been shown here that an active NF-<jats:italic>κ</jats:italic>B signalling pathway is a general prerequisite for influenza virus infection of human cells. Cells with low NF-<jats:italic>κ</jats:italic>B activity were resistant to influenza virus infection, but became susceptible upon activation of NF-<jats:italic>κ</jats:italic>B. In addition, blocking of NF-<jats:italic>κ</jats:italic>B activation severely impaired influenza virus infection of otherwise highly susceptible cells, including the human lung carcinoma cell lines A549 and U1752 and primary human cells. On the other hand, infection with vaccinia virus was not dependent on an active NF-<jats:italic>κ</jats:italic>B signalling pathway, demonstrating the specificity of this pathway for influenza virus infection. These results might be of major importance for both the development of new antiviral therapies and the understanding of influenza virus biology.</jats:p>

収録刊行物

被引用文献 (6)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ